STERIS plc

NYSE:STE Voorraadrapport

Marktkapitalisatie: US$21.2b

STERIS Toekomstige groei

Future criteriumcontroles 1/6

STERIS zal naar verwachting groeien in winst en omzet met respectievelijk 9.5% en 6.2% per jaar. De winst per aandeel zal naar verwachting groeien met 9.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 12.8% zijn.

Belangrijke informatie

9.5%

Groei van de winst

9.57%

Groei van de winst per aandeel

Medical Equipment winstgroei16.1%
Inkomstengroei6.2%
Toekomstig rendement op eigen vermogen12.80%
Dekking van analisten

Good

Laatst bijgewerkt13 May 2026

Recente toekomstige groei-updates

Recent updates

Narratiefupdate • May 11

STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside

Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.
Narratiefupdate • Apr 26

STE: Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).
Narratiefupdate • Apr 11

STE: Completed Buyback And Stable Assumptions Will Support Future Upside

Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.
Narratiefupdate • Mar 28

STE: Completed Buyback And Refined Assumptions Will Support Future Upside

Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.
Analyseartikel • Mar 24

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...
Narratiefupdate • Mar 11

STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.
Narratiefupdate • Feb 25

STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside

Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.
Narratiefupdate • Feb 10

STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View

Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.
Seeking Alpha • Feb 06

STERIS: A Bump In The Road For A Reliable Name

Summary STERIS offers a resilient, high-quality business model with some premium valuation, benefiting from hard-to-replicate sterilization networks and stable healthcare procedure volumes. Recent quarterly results included on-target 8% organic revenue growth but margin pressure from tariffs, with management raising tariff impact guidance by $10 million. STE stands to gain from stricter ethylene oxide (EtO) regulations, as compliance costs favor large, established players and will drive more outsourcing to its facilities. While not deeply undervalued, STE provides credible GARP appeal, stable cash flows, and less execution risk versus more volatile medtech peers. Read the full article on Seeking Alpha
Narratiefupdate • Jan 27

STE: Share Repurchases And Stable Outlook Will Support A Fair View

Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).
Narratiefupdate • Jan 10

STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook

Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.
Analyseartikel • Jan 09

Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analyseartikel • Dec 26

Earnings Tell The Story For STERIS plc (NYSE:STE)

With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...
Narratiefupdate • Dec 23

STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook

Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).
Narratiefupdate • Dec 09

STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook

Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).
Narratiefupdate • Nov 25

STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance

Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.
Narratiefupdate • Nov 07

STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value

Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.
Analyseartikel • Oct 27

Is STERIS (NYSE:STE) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Narratiefupdate • Sep 05

Healthcare Demand And Facility Expansion Will Create Value

With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.
Analyseartikel • Aug 28

Calculating The Fair Value Of STERIS plc (NYSE:STE)

Key Insights STERIS' estimated fair value is US$227 based on 2 Stage Free Cash Flow to Equity With US$249 share price...
Analyseartikel • Aug 07

STERIS (NYSE:STE) Is Paying Out A Larger Dividend Than Last Year

The board of STERIS plc ( NYSE:STE ) has announced that it will be increasing its dividend by 11% on the 26th of...
Analyseartikel • Jul 06

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

STERIS plc ( NYSE:STE ) saw a double-digit share price rise of over 10% in the past couple of months on the NYSE. The...
Seeking Alpha • Mar 22

Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'

Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking Alpha
Seeking Alpha • Nov 18

Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'

Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking Alpha
Seeking Alpha • Sep 16

Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued

Summary I reiterate a 'Hold' rating for Steris stock with a fair value of $220 per share, citing strong healthcare growth and overvaluation concerns. The divestiture of the dental business and acquisition of Surgical Instrumentation assets will allow Steris to focus on core healthcare and AST businesses. Steris reported 5.4% organic revenue growth and 7% adjusted EPS growth, driven by a 7.2% increase in AST business and strong healthcare performance. Despite strategic moves, cautious outlook on healthcare capital equipment spending due to high-interest rates supports maintaining a 'Hold' rating. Read the full article on Seeking Alpha
User avatar
Nieuw narratief • Aug 20

Robust Revenue Growth And Expanding Margins In The Medical Equipment Sector

Strong start to the fiscal year and gross margin improvements suggest underappreciated growth momentum and potential for expanding net margins.
Seeking Alpha • Aug 13

Steris: Q2 Numbers Solidify Buy Thesis

Summary STE's Q1 FY'25 numbers were in line with expectations, with upsides in the healthcare and AST divisions. The company shows consistent free cash flow production and stable earnings on its capital base. I've revised our estimate on the intrinsic worth of the business to $270 per share, reiterating a buy. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NYSE:STE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/20297,1861,045N/AN/A2
3/31/20286,7729849781,4277
3/31/20276,3618878441,2758
3/31/20265,9367829721,341N/A
12/31/20255,8287099171,267N/A
9/30/20255,7026899611,301N/A
6/30/20255,5716489091,264N/A
3/31/20255,4606107781,148N/A
12/31/20245,3986177511,142N/A
9/30/20245,3265916801,101N/A
6/30/20245,235561594996N/A
3/31/20245,139551613973N/A
12/31/20234,6831,036594934N/A
9/30/20234,6011,012535849N/A
6/30/20234,563576494806N/A
3/31/20234,536557395757N/A
12/31/20224,784-28349713N/A
9/30/20224,777-8399752N/A
6/30/20224,773377472819N/A
3/31/20224,223285397685N/A
12/31/20214,248279412701N/A
9/30/20213,848250400662N/A
6/30/20213,407286424653N/A
3/31/20213,108397450690N/A
12/31/20203,057433476701N/A
9/30/20203,022424400627N/A
6/30/20203,003413384615N/A
3/31/20203,031408376591N/A
12/31/20192,976393N/A570N/A
9/30/20192,898336N/A573N/A
6/30/20192,840319N/A548N/A
3/31/20192,782304N/A540N/A
12/31/20182,730269N/A490N/A
9/30/20182,696316N/A467N/A
6/30/20182,651303N/A478N/A
3/31/20182,620291N/A458N/A
12/31/20172,585243N/A463N/A
9/30/20172,570144N/A453N/A
6/30/20172,582120N/A424N/A
3/31/20172,613110N/A424N/A
12/31/20162,616142N/A439N/A
9/30/20162,588167N/A364N/A
6/30/20162,431135N/A294N/A
3/31/20162,233111N/A255N/A
12/31/20152,04294N/A185N/A
9/30/20151,897113N/A221N/A
6/30/20151,870135N/A241N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei STE ( 9.5% per jaar) ligt boven de spaarquote ( 3.5% ).

Winst versus markt: De winst van STE ( 9.5% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16.8% per jaar).

Hoge groeiwinsten: De winst van STE zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van STE ( 6.2% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.7% per jaar).

Hoge groei-inkomsten: De omzet van STE ( 6.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen STE zal naar verwachting over 3 jaar laag zijn ( 12.8 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/24 19:35
Aandelenkoers aan het einde van de dag2026/05/22 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2026/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

STERIS plc wordt gevolgd door 18 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Michael PolarkBaird
Erin Wilson WrightBofA Global Research
David TurkalyCitizens JMP Securities, LLC